Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dallah Healthcare CoSAU:4004 -2.00%89 EV-to-EBITDA is 16.63 as of Sep. 21, 2026, which is 21% below its 10-year median of 20.96. GuruFocus rates SAU:4004 with a GF Score™ of 89/100 and a GF Value™ of ﷼165.23 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Dallah Healthcare Co ranks worse than 71.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dallah Healthcare Co's enterprise value is ﷼13,730 Mil.
Dallah Healthcare Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ﷼826 Mil. Therefore, Dallah Healthcare Co's EV-to-EBITDA for today is 16.63.
The historical rank and industry rank for Dallah Healthcare Co's EV-to-EBITDA or its related term are showing as below:
SAU:4004'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.9 Med: 20.96 Max: 35.46
Current: 15.68
During the past 13 years, the highest EV-to-EBITDA of Dallah Healthcare Co was 35.46. The lowest was 12.90. And the median was 20.96.
SAU:4004's EV-to-EBITDA is ranked worse than 71.51% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 10.09
vs SAU:4004: 15.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dallah Healthcare Co (SAU:4004) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dallah Healthcare Co's PE Ratio (TTM) for today is calculated as:
Dallah Healthcare Co's share price for today is ﷼78.40.
Dallah Healthcare Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼3.652.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Dallah Healthcare Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAU:4004 vs HCA, THC, EHC: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Dallah Healthcare Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dallah Healthcare Co EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dallah Healthcare Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dallah Healthcare Co's EV-to-EBITDA falls into.
Dallah Healthcare Co's current Enterprise Value is ﷼13,730 Mil.
Dallah Healthcare Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ﷼826 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dallah Healthcare Co (SAU:4004) has a EV-to-EBITDA of 16.63 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dallah Healthcare Co. This is 21% below median its historical median of 20.96. Over the past decade, Dallah Healthcare Co's EV-to-EBITDA has ranged from 12.90 to 35.46. According to the industry distribution chart, Dallah Healthcare Co ranks #374 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 71.5%.
Is Dallah Healthcare Co's EV-to-EBITDA too high?
Dallah Healthcare Co's current EV-to-EBITDA of 16.63 is 21% below median its 10-year median of 20.96. Over the past 10 years, this metric has ranged from a low of 12.90 to a high of 35.46. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.09. Dallah Healthcare Co's value of 16.63 is 64.8% above this industry median. Based on the distribution chart, Dallah Healthcare Co ranks #374 out of 523 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dallah Healthcare Co has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dallah Healthcare Co's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dallah Healthcare Co ranks #374 out of 523 companies for EV-to-EBITDA. This places Dallah Healthcare Co in the lower half of its industry. The industry median EV-to-EBITDA is 10.09. Dallah Healthcare Co's value of 16.63 is 64.8% above this benchmark. Historically, Dallah Healthcare Co's own EV-to-EBITDA has ranged from 12.90 to 35.46 over the past decade. While the company's 10-year median is 20.96 vs. the industry median of 10.09, Dallah Healthcare Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.09, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dallah Healthcare Co's current EV-to-EBITDA of 16.63 is 64.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dallah Healthcare Co. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dallah Healthcare Co's current EV-to-EBITDA is 16.63, which is 21% below median its own 10-year median of 20.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dallah Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Dallah Healthcare Co (SAU:4004) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼165.23, compared to a current price of ﷼78.40 — trading 52.6% below its estimated fair value. The current EV-to-EBITDA is 16.63, which is 21% below median its 10-year median of 20.96 and 64.8% above the Healthcare Providers & Services industry median of 10.09. Dallah Healthcare Co's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dallah Healthcare Co (SAU:4004), the current EV-to-EBITDA is 16.63 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dallah Healthcare Co (SAU:4004) Overvalued in 2026?
Based on GuruFocus' analysis, Dallah Healthcare Co stock appears to be undervalued.
The current stock price of ﷼78.40 is trading 52.6% below its estimated GF Value™ of ﷼165.23.
GuruFocus considers Dallah Healthcare Co to be Significantly Undervalued.
Key valuation signals for SAU:4004:
EV-to-EBITDA: 16.63 (21% below median its 10-year median of 20.96)
GF Value™: ﷼165.23 vs. price of ﷼78.40 (52.6% below fair value)
Industry Position: 64.8% above the Healthcare Providers & Services median (#374 of 523)
No single metric tells the full story. See the SAU:4004 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dallah Healthcare Co provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The objectives of the company include operating, managing, and maintaining the healthcare entities, wholesale medicines, and retail of medical and surgical equipment, prosthetics, and devices for the disabled, hospital equipment, and manufacturing medicines, pharmaceuticals, herbals, health, cosmetics, detergents, disinfectants, and packaging in the Kingdom of Saudi Arabia. The reportable segments of the company are Medical Facilities and Pharmacies, and Distribution of Pharmaceutical Products. The company generates the majority of its revenue from the Medical Facilities and Pharmacies segment.
89GF Score
Get the complete analysis for SAU:4004
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4004 has been successfully added to your 
